Prognosis Prediction of CRAFITY Score in HCC Undergoing TACE Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapy

医学 内科学 肝细胞癌 置信区间 胃肠病学 统计显著性 免疫疗法 比例危险模型 无进展生存期 不利影响 肿瘤科 总体生存率 癌症
作者
Ze-Xin Hu,Xiao-Yang Xu,Ze Wang,Jintao Huang,Wan-Ci Li,Shuai Zhang,Jian Shen,Bin‐Yan Zhong,Xiaoli Zhu
出处
期刊:Journal of Hepatocellular Carcinoma [Dove Medical Press]
卷期号:Volume 10: 2073-2082 被引量:2
标识
DOI:10.2147/jhc.s439660
摘要

The CRAFITY (C-reactive protein and alpha-fetoprotein in immunotherapy) score has demonstrated prognostic significance in hepatocellular carcinoma (HCC) patients undergoing immunotherapy. The study aimed to validate accuracy of CRAFITY score on predicting prognosis for patients with HCC treated with transarterial chemoembolization (TACE) combined with PD-(L)1 inhibitors and molecular targeted therapy.Eighty-five HCC patients who underwent TACE in combination with molecular targeted therapy (MTT) and PD-(L)1 Inhibitors were consecutively enrolled from November 2019 to November 2022. Patients were divided into CRAFITY 0 score (n=32), CRAFITY 1 score (n=31), and CRAFITY 2 score (n=22), respectively. The primary outcomes were overall survival (OS) and progression-free survival (PFS), and the secondary outcomes included tumor response rate and treatment-related adverse events (TRAEs). Factors affecting survival were identified via Cox regression analysis.The median overall survival (OS) for HCC patients with CRAFITY scores of 0, 1, and 2 was 33.4 months (95% confidence interval [CI]: 27.1-39.7), 34.5 months (95% CI: 23.1-45.9), and 24.2 months (95% CI: 13.9-39.3), respectively, there were statistical differences among the three groups (p<0.05). The progression-free survival (PFS) was 14.1 months (95% CI: 10.0-18.2), 14.1 months (95% CI: 9.0-19.2), and 9.3 months (95% CI: 7.2-11.4) for patients with CRAFITY scores of 1, 2, and 3, respectively, with a significant difference between the three groups (p<0.05). In patients with CRAFITY scores of 1, 2, and 3, the disease control rates (DCR) were 94%, 84%, and 73%, respectively (p < 0.05), while the overall response rates (ORR) were 78.1%, 67.7%, and 59.1%, respectively (p = 0.318). A higher CRAFITY score showed a correlation with an increased frequency of fatigue and grade 3 fever (p<0.05). Moreover, CRAFITY 2 score was an independent risk factor for both OS (HR = 2.610(1.281-4.564), p = 0.014) and PFS (HR = 2.419(1.281-4.564), p = 0.006).The CRAFITY score may provide an efficient predictive capacity for prognosis in HCC patients undergoing TACE combined with PD-(L)1 inhibitors and molecular targeted therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
KuchA完成签到,获得积分10
刚刚
Agiff完成签到 ,获得积分10
3秒前
黄油小熊完成签到 ,获得积分10
3秒前
大胆的小土豆完成签到 ,获得积分10
3秒前
学术小白完成签到,获得积分10
4秒前
留胡子的垣完成签到,获得积分10
4秒前
完美世界的应助被爱在西元前采纳,获得10
4秒前
5秒前
左江夜渔人完成签到,获得积分10
5秒前
小武完成签到,获得积分10
6秒前
DW的应助被活泼的断秋采纳,获得10
6秒前
爱始终年轻完成签到,获得积分10
6秒前
呼呼呼完成签到,获得积分10
6秒前
高大无声完成签到,获得积分10
8秒前
汐儿完成签到 ,获得积分10
8秒前
爱在西元前完成签到,获得积分20
10秒前
大宝君发布了新的文献求助10
11秒前
KuangLH完成签到,获得积分10
11秒前
11秒前
hongw_liu完成签到,获得积分10
13秒前
13秒前
14秒前
Rita完成签到 ,获得积分10
14秒前
热可可728完成签到,获得积分10
15秒前
jiazicha完成签到,获得积分10
15秒前
wuhu完成签到,获得积分10
15秒前
庄海棠完成签到 ,获得积分0
15秒前
苦无发布了新的文献求助10
16秒前
深情千雁完成签到,获得积分10
16秒前
ChiZhiXing完成签到 ,获得积分10
17秒前
Borw完成签到,获得积分10
18秒前
zjw完成签到,获得积分10
18秒前
萱棚完成签到 ,获得积分10
21秒前
RH完成签到,获得积分10
21秒前
橙橙橙完成签到 ,获得积分10
21秒前
aku30完成签到,获得积分10
23秒前
Hzz完成签到,获得积分10
23秒前
24秒前
Yingqian_Zhang完成签到 ,获得积分10
25秒前
优雅的千凝完成签到,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180111
求助须知:如何正确求助?哪些是违规求助? 9570235
关于积分的说明 21809065
捐赠科研通 7776183
什么是DOI,文献DOI怎么找? 3433262
关于科研通互助平台的介绍 2557463
邀请新用户注册赠送积分活动 2479038